Company profilePharmaceutical#192 of 1,318 in Pakistan✓ No DRAP alerts

GOODMAN INTERNATIONAL,

Pharmaceutical company · 94 brands · 81 molecules

Ranked #51 of 62 companies in Antivirals For Systemic Use

94 registered products 32 pharmaceutical brands 81 distinct molecules 0 DRAP alerts

Company overview

94
registered products
32
pharmaceutical brands
81
distinct molecules
2
therapeutic classes
0
DRAP alerts

GOODMAN INTERNATIONAL, is a pharmaceutical manufacturer registered with the Drug Regulatory Authority of Pakistan, holding 94 product registrations across 81 distinct molecules. It is the 192nd largest registrant in Pakistan by product count, and ranks 51st of 62 in Antivirals For Systemic Use. Its portfolio is concentrated in Antivirals For Systemic Use and Skin Conditions. It has no DRAP recall, shortage or safety notices on record.

Compiled from the DRAP registry, DRAP approved prices and DRAP alerts, with observed retail from DVAGO and Servaid. Data as of 2026-07-30.

Products by GOODMAN

1 product matched in our catalogue — each with its observed price and DRAP approved ceiling.

Skin Conditions 1

Top molecules by brand count

Diclofenac5 brands
Lumefantrine3 brands
Artemether3 brands
Alendronate3 brands
Ceftriaxone3 brands
Omeprazole2 brands
Piroxicam2 brands
Cefoperazone2 brands
Famotidine2 brands

Therapeutic classes

Antivirals For Systemic Use · 1Skin Conditions · 1

Conditions treated

Acne/Oral · 1

Price band (DRAP official ceilings)

Registered products priced by source
Servaid1 products · Rs 699 – Rs 699
Median across source: Rs 699

Regulatory record

No DRAP alerts on record

No recalls, shortage notices or safety alerts involving this company’s products appear in the DRAP alert feed we track. Median across all 1,318 mapped companies is zero — 1,165 of them also have a clean sheet.

Competitive set

Companies whose registered portfolio overlaps most with this one.

SHROOQ PHARMACEUTICALS39 shared molecules
BIO LABS (PVT) LTD.35 shared molecules
NEUTRO PHARMA (PVT) LTD.34 shared molecules
FYNK PHARMACEUTICALS32 shared molecules
Albro Pharmaceuticals31 shared molecules

Portfolio whitespace

Molecules the closest competitors have registered and this company has not — the starting point for a launch shortlist.

SHROOQ PHARMACEUTICALS holds 22 molecules not in this portfolio
AcitretinAcyclovirAcyclovir Inf/OralCefiximeCiprofloxacinDiclofenac
ENGLISH PHARMACEUTICALS INDUSTRIES holds 70 molecules not in this portfolio
000 I.UAmikacinAmoxicillinAmoxicillin BaseAmoxycillin BaseAmpicillin
GENOME PHARMACEUTICALS (PVT) LTD holds 112 molecules not in this portfolio
AcitretinAmlodipineAnastrazoleAnastrozoleAprepitantArtemether

Get the full profile for GOODMAN

This page is a summary. The full company brief adds every registration with its approved ceiling and approval date, per-molecule competitive position, price positioning against the category, and a launch shortlist built from the whitespace above.

Request this brief See what’s included

Company data as of 2026-07-30. Brand and molecule counts from the DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.